These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 26412559)

  • 1. Platelet function recovery following exposure to triple anti-platelet inhibitors using an in vitro transfusion model.
    Bhal V; Herr MJ; Dixon M; Akins S; Hord E; White MM; Seiffert D; Kotha J; Jennings LK
    Thromb Res; 2015 Dec; 136(6):1216-23. PubMed ID: 26412559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normalization of platelet reactivity in clopidogrel-treated subjects.
    Vilahur G; Choi BG; Zafar MU; Viles-Gonzalez JF; Vorchheimer DA; Fuster V; Badimon JJ
    J Thromb Haemost; 2007 Jan; 5(1):82-90. PubMed ID: 17239165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to antiplatelet therapy is independent of endogenous thrombin generation potential.
    Gremmel T; Panzer S; Steiner S; Seidinger D; Koppensteiner R; Pabinger I; Kopp CW; Ay C
    Thromb Res; 2013 Jul; 132(1):e24-30. PubMed ID: 23623170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist.
    Cai TQ; Wickham LA; Sitko G; Michener MS; Raubertas R; Handt L; Chintala M; Seiffert D; Forrest M
    Eur J Pharmacol; 2015 Jul; 758():107-14. PubMed ID: 25857224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation.
    Sbrana S; Della Pina F; Rizza A; Buffa M; De Filippis R; Gianetti J; Clerico A
    Cytometry B Clin Cytom; 2008 Jan; 74(1):30-9. PubMed ID: 17630652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
    Bal Dit Sollier C; Berge N; Boval B; Dubar M; Drouet L
    Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy.
    Gremmel T; Koppensteiner R; Panzer S
    PLoS One; 2015; 10(6):e0129666. PubMed ID: 26058047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preserved thrombin-inducible platelet activation in thienopyridine-treated patients.
    Gremmel T; Kopp CW; Seidinger D; Koppensteiner R; Steiner S; Panzer S
    Eur J Clin Invest; 2013 Jul; 43(7):689-97. PubMed ID: 23611368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty.
    Gremmel T; Xhelili E; Steiner S; Koppensteiner R; Kopp CW; Panzer S
    Atherosclerosis; 2014 Jan; 232(1):119-24. PubMed ID: 24401225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the aggregation responses of camel platelets.
    Al Ghumlas AK; Gader AG
    Vet Clin Pathol; 2013 Sep; 42(3):307-13. PubMed ID: 23919654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of P2Y12 inhibition on platelet activation assessed with aggregation- and flow cytometry-based assays.
    Leunissen TC; Wisman PP; van Holten TC; de Groot PG; Korporaal SJ; Koekman AC; Moll FL; Teraa M; Verhaar MC; de Borst GJ; Urbanus RT; Roest M
    Platelets; 2017 Sep; 28(6):567-575. PubMed ID: 27885904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
    O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
    Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
    Badr Eslam R; Lang IM; Kaider A; Panzer S
    Transl Res; 2013 May; 161(5):414-20. PubMed ID: 23313628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome.
    Xiao Z; Théroux P
    J Am Coll Cardiol; 2004 Jun; 43(11):1982-8. PubMed ID: 15172401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition.
    Björkman JA; Zachrisson H; Forsberg GB; von Bahr H; Hansson GI; Warner TD; Nylander S
    Thromb Res; 2013 Apr; 131(4):313-9. PubMed ID: 23419412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
    Ueno M; Ferreiro JL; Desai B; Tomasello SD; Tello-Montoliu A; Capodanno D; Capranzano P; Kodali M; Dharmashankar K; Charlton RK; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2012 Mar; 5(3):293-300. PubMed ID: 22440495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
    Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
    J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.